Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹99 | ₹100 |
Expense Ratio | 1.93 | 1.92 |
NAV | ₹36.85 | ₹37.42 |
Fund Started | 11 Jun 2018 | 25 Jun 2018 |
Fund Size | ₹2770.21 Cr | ₹5024.00 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 37.12% | 47.43% |
3 Year | 16.84% | 23.16% |
5 Year | 28.20% | 30.01% |
1 Year
3 Year
5 Year
Equity | 99.08% | 97.87% |
Cash | 0.92% | 2.13% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.00% |
Aurobindo Pharma Ltd. | 8.05% |
Cipla Ltd. | 6.80% |
Glenmark Pharmaceuticals Ltd. | 6.20% |
Dr. Reddy's Laboratories Ltd. | 6.05% |
Apollo Hospitals Enterprise Ltd. | 5.51% |
Lupin Ltd. | 5.30% |
Divi's Laboratories Ltd. | 4.96% |
Suven Pharmaceuticals Ltd. | 4.22% |
Krishna Institute of Medical Sciences Ltd | 3.95% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 14.35% |
Dr. Reddy's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 8.07% |
Lupin Ltd. | 4.59% |
Aurobindo Pharma Ltd. | 4.57% |
Gland Pharma Ltd. | 4.22% |
Apollo Hospitals Enterprise Ltd. | 3.80% |
Zydus Lifesciences Ltd. | 2.93% |
Divi's Laboratories Ltd. | 2.69% |
Biocon Ltd. | 2.39% |
Name | Vrijesh Kasera | Dharmesh Kakkad |
Start Date | 03 Feb 2023 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 11 Jun 2018 | 25 Jun 2018 |
Description
Launch Date